Articles tagged with Vaccination
A new study published in PLOS Pathogens found that whooping cough immunity typically lasts at least 30 years and perhaps as long as 70 years after natural infection. The research suggests that repeat infections contribute relatively little to transmission and may even boost immunity in individuals with waning protection.
The first ever World Pneumonia Day highlights the potential for renewed global action against this forgotten killer of children. The Global Action Plan for Prevention and Control of Pneumonia aims to reduce child pneumonia mortality through exclusive breastfeeding, vaccine use, and community-level management.
Researchers at UC Davis MIND Institute report that after adjusting for factors, typically developing children and those with autism have similar blood-mercury levels. The study, conducted as part of the CHARGE Study, looked at various sources of mercury in participants' environments, including fish consumption and vaccinations.
The American College of Physicians (ACP) has issued clinical practice guidelines for treating erectile dysfunction (ED), recommending the use of phosphodiesterase type 5 (PDE-5) inhibitors and individualizing decisions on hormonal tests. For patients with stable ischemic heart disease, adding ACE inhibitors to standard care improves ou...
A systematic review of six randomized trials found pneumococcal conjugate vaccines reduced vaccine-type IPD by 80%, all-serotype IPD by 58% and x-ray defined pneumonia by 27%. The vaccines also prevented 11% of child deaths.
A national survey found that most girls and young women were aware of the HPV vaccine's benefits, but lacked knowledge about the HPV virus and other sexually transmitted infections. The study suggests that education on the HPV virus itself is crucial for informed decision-making.
Veterinary scientists harnessing 'barcodes' of microbes to develop a single, effective vaccine for all mammals. Tiny variations in TLRs could be key to adapting vaccines across species.
A University of North Carolina at Chapel Hill researcher has been awarded a four-year grant to study the effectiveness of rotavirus vaccines in Nicaragua. The study aims to determine how well the vaccine works in developing countries and identify shifts in rotavirus strains as a result of immunization programs.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded contracts to discover novel vaccine adjuvants. The goal is to enhance the immune response and extend vaccine supply. Researchers will test new compounds in animal models and human cells.
A new article reviews published research and finds no convincing evidence supporting a relationship between vaccines and autism. The onset of autism occurs prior to age three, with various possible associations examined but no clear cause identified.
A new method of delivering measles vaccines, using an inhalable powder, has shown promise in test animals. The powder is produced by mixing a weakened measles virus with high-pressure carbon dioxide and can remain stable for at least eight weeks at room temperature.
Vaccination against HPV, combined with national screening programmes, could lead to the eradication of cervical cancer in countries that implement such measures. HPV screening is more effective than Pap smear tests and can detect the virus in smears rather than relying on visual examination.
A team of researchers led by Dr. Alon Monsonego has created a humanized mouse model that responds specifically to an A-beta-peptide vaccine, reducing plaque and inflammation in the brain. The study provides a basis for developing individualized immunotherapeutic approaches to Alzheimer's disease.
A new rabies vaccine has shown to induce a rapid and efficient immune response in mice and non-human primates, potentially reducing the six-shot post-exposure regimen to just one inoculation. The experimental vaccine lacks a key gene called the matrix (M) gene, inhibiting the virus from completing its life cycle.
The MSD Wellcome Trust Hilleman Laboratories aims to develop new vaccines to prevent diseases affecting low-income countries. The not-for-profit joint venture will work on optimizing existing vaccines and developing new ones, with the goal of increasing vaccine impact in resource-limited settings.
A 20-year study revealed a significant drop in liver cancer cases among vaccinated 6- to 19-year-olds. The universal vaccination program in Taiwan has been shown to extend its effectiveness into young adulthood.
A study published in The Lancet found that vaccination against bacterial infections, such as Streptococcus pneumoniae and Haemophilus influenzae type b, can substantially improve survival rates in African children with sickle-cell anaemia. The researchers also found that these bacteria are the same cause of infection in both developed ...
A new protein conjugate vaccine, PCV7, has been found to produce superior immune responses in patients with chronic obstructive pulmonary disease (COPD) compared to the currently accepted vaccine, PPSV23. The study suggests that PCV7 may offer improved protection against respiratory disease in COPD patients at risk for pneumonia.
Researchers at the University of British Columbia have developed a system that turns harmless bacterium Caulobacter crescentus into a protein production factory, making useful proteins for vaccines and therapeutic purposes. The technology could be used to manufacture HIV-blocking agents cheaply and with minimal expertise.
Einstein scientists have identified two small protein fragments that could be developed into an anthrax vaccine, potentially causing fewer side effects than the current vaccine. The research focuses on the protein toxin used in the current vaccine, looking for peptides that can trigger protective antibodies when injected into animals.
Researchers found that patients with aggressive leukemia had few complications and mounted a strong immune system attack after receiving a cancer vaccine shortly after a stem cell transplant. The study suggests that the approach may be more effective than traditional transplant alone, with higher survival rates.
The study analyzed reports of adverse events following HPV vaccination and found a higher proportion of reports of fainting and blood clots. However, the rates were still consistent with pre-licensing data and background rates of other vaccines.
New vaccines, drug regimens, and diagnostics under development have the potential to significantly impact tuberculosis. The study predicts a 39-52% decrease in TB incidence through vaccination, while new drug regimens could reduce incidence by 10-27%. Diagnostic tools may also contribute to improved outcomes.
A new monitoring system developed by Johns Hopkins researchers allows for the non-invasive pinpointing of Mycobacterium tuberculosis in mouse lungs, speeding up preclinical testing of TB drugs and vaccines. This innovation enables fewer animals to be used, reducing the need for lengthy and complicated regimens.
A new study by IVI-NICED found that the Vi polysaccharide vaccine is highly effective in protecting young children against typhoid fever, with 80% protection rate in children under five years old. The vaccine also conferred substantial herd protection, reducing typhoid risk among unvaccinated neighbors by 44%.
The study shows that the timing of rotavirus epidemics depends on birth rates in the population, with higher birth rates leading to earlier outbreaks. New vaccines may reduce the frequency and severity of these outbreaks, potentially shifting the age at which infection appears in children.
Researchers at La Jolla Institute have discovered the specific gene that triggers antibody production, a key step in mounting an immune response against viruses and pathogens. The finding has significant implications for developing new and more effective vaccines.
A study found that reduced-dose schedules of pneumococcal conjugate vaccine (PCV-7) significantly reduce vaccine serotype pneumococcal carriage in children. The 2-dose and 2 + 1-dose schedules were shown to be effective in reducing pneumonia and infection risks in infants.
A study published in JNCI found HPV vaccination to be non-cost-effective in the Netherlands due to low cervical cancer cases and deaths. The authors suggest vaccine price reduction could make it more cost-effective, but only if the vaccine's effectiveness increases.
Researchers have mapped the structure of an antiviral antibody clamped onto rotavirus protein VP7, revealing intimate details about how it interferes with virus infection. The discovery may lead to the development of a new generation of rotavirus vaccines that are easier to store and administer.
Researchers have found that CSA-13, a synthetic compound, can kill vaccinia virus in cell cultures and mice, while also stimulating the innate immune system. The study showed that CSA-13 reduced skin lesions caused by vaccinia virus in infected mice.
Researchers at the University of Pennsylvania School of Medicine have found that metformin can enhance the effectiveness of vaccines by boosting numbers of cancer-fighting T cells. This resulted in a larger population of memory immune cells that were able to fight off a tumor at a later time.
Researchers discovered that metformin increases the efficiency of T-cells, which boosts infection- and cancer-fighting treatments. This discovery could lead to novel strategies for vaccine and anti-cancer therapies, potentially enhancing immunological memory.
A recent Florida State University study found that informing men about the HPV vaccine's benefit for their female partners did not increase their interest in getting the vaccine. The researchers suggest that men may need more direct information on the vaccine's benefits for their own health to consider vaccination.
A randomized trial found the HPV vaccine to be 91% effective against all four virus strains in women aged 24-45 who hadn't been infected. The vaccine efficacy was lower when including those with pre-existing HPV infection, highlighting the importance of vaccinating susceptible individuals.
The study found that those who received the vaccine had a significant response rate of 22.1% and progression-free survival of 2.9 months compared to 9.7% and 1.6 months respectively in those that did not. The median overall survival for those receiving vaccine trended positive at 17.6 months.
The vaccine-autism debate persists despite scientific consensus, fueled by internet misinformation and declining public trust. Pediatrician Paul Offit's efforts to set the record straight have been hindered by celebrity anti-vaccine advocates like Jenny McCarthy.
A new multimeric-L2 protein vaccine shows robust antibody responses and protection against human papillomavirus (HPV) infection in mice and rabbits. The vaccine has the potential to address the limited protection of current HPV vaccines against other HPV types, which cause cancer.
Researchers at La Jolla Institute have identified a cellular defect that increases the risk of severe reactions to the smallpox vaccine in people with eczema. Boosting Natural Killer cell activity may help prevent such reactions.
Researchers have developed a new computer simulation model that captures the human immune response to influenza type A, predicting treatment design and pandemic preparedness. The model reveals that drugs and vaccines targeting dendritic cell presentation of antigens have a significant impact on patient outcomes.
A potential vaccine for Alzheimer's disease has been shown to slow the weakening of muscles associated with inclusion body myositis (IBM) in mice. The study found reduced levels of beta amyloid and oligomeric beta amyloid, a more toxic form, in the skeletal muscle tissue.
The European Union has awarded $4 million to support the development of new antibiotics and vaccines against pneumococcal infections. Researchers from 13 international institutions are working together to combat this deadly disease, which claims over 60,000 lives annually in Germany alone.
A paper in The Lancet raises concerns about the Gates Foundation's allocation of funds, with 65% going to just 20 organizations. The authors suggest improving governance, transparency and accountability, as well as investing more in health systems and research capacity in low-income countries.
Vaccine refusal puts children at risk of infectious diseases like measles and pertussis, even if parents are vaccinated. Healthcare providers can play a critical role in explaining the benefits of immunization and addressing parental concerns.
A study by Case Western Reserve University found that vaccination records may not accurately predict a child's protection from disease, even with valid written records. Serologic testing revealed immunization levels did not consistently match those of the written records.
Identifying a transcription factor that regulates blood stem cells, researchers found ELF4 activates an inhibitor that stops naive T cells from proliferating. This discovery could lead to better vaccines and more effective cancer immunotherapy by controlling T cell growth and production.
Researchers found that after reassortment with a human influenza virus, an avian flu virus requires relatively few mutations to spread rapidly between mammals by respiratory droplets. This process is similar to the formation of the current swine flu outbreak, suggesting a potential link between avian and human influenza viruses.
A MSU researcher has developed a working vaccine for Enterotoxigenic E. coli, responsible for 60% of all E. coli diarrheal disease. The vaccine could save untold lives and also provide relief from post-operative complications such as paralytic ileus and urinary retention.
Physicians from the Catholic University of Rome assessed health conditions of 150 children living with mothers in prison. Environmental factors and early weaning are linked to premature birth, hypertension, and allergy risk. Vaccination status is also a concern, with only 14% of jail-bound children fully vaccinated.
A new study from the University of Missouri found that newborns' immune systems require time to mature before responding effectively to vaccines. This slow maturation can lead to an overabundance of Th-2 cells, which can cause allergic reactions and make infants more susceptible to infections.
Rising temperatures and mild winters have led to increased outbreaks of bluetongue and other insect-transmitted viruses in European livestock, with devastating consequences for ruminants. The UK successfully suppressed a major outbreak in 2008, but new virus types pose ongoing threats to the region.
A population-based study found that HPV16 and HPV18 genotypes were present in the majority of invasive cervical cancers in New Mexico. The mean age of women diagnosed with HPV16- or HPV18-positive cancer was 5 years younger than that of women diagnosed with other HPV types, suggesting implications for future cancer screening.
A study of nearly 218,000 children across 45 low-income and middle-income countries found significant delays in vaccination timing, with some countries experiencing delays of over 10 weeks for certain vaccines. The study highlights the need for improved vaccine coverage and timeliness to protect children from preventable diseases.
A new vaccine is being tested to prevent colon cancer by stimulating an immune response against the MUC1 protein in precancerous growths. The vaccine has shown promise in generating an immune response despite weakened immune systems, suggesting it may stop polyps from transforming into malignant tumors.
A Phase II clinical trial found that the vaccine showed efficacy in mothers, with a significantly lower rate of CMV infection. The study used an experimental vaccine made from glycoprotein B and included an adjuvant to improve immune response.
A new experimental vaccine has shown promising results in preventing cytomegalovirus (CMV) infection in infants, reducing the risk by 50% compared to a saline injection. The vaccine was given to 441 CMV-negative women and found to be safe with minimal side effects.
A new Norwegian study suggests that HPV vaccination can prevent up to 35-128 preterm births per 100,000 births by reducing the risk of surgical treatment after cervical cell changes. The vaccine may have an important impact on preventing extremely preterm births.
A study by Massachusetts General Hospital found that both Latino and non-Latino women are more likely to accept HPV vaccination for themselves and their children than previously reported. The main motivator for these women is the prevention of cancer, with no association between vaccine acceptance and income or education level.
A new strategy to enhance the BCG vaccine's effectiveness has shown superior protection against tuberculosis in a pre-clinical test. By neutralizing the bacteria's evasive mechanisms, researchers have increased the number of TB organisms killed and duration of protection by threefold.
A new study published in the Journal of Leukocyte Biology suggests that interferon can improve the effectiveness of the current tuberculosis vaccine by enhancing dendritic cell function. The research found that type I interferon stimulated dendritic cells to produce a stronger immune response against Mycobacterium tuberculosis.